NXGL
NEXGEL, Inc.1.6400
+0.0500+3.14%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
13.35MP/E (TTM)
-Basic EPS (TTM)
-0.37Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
Q2 FY2025 results
NexGel doubled revenues to $2.9M in Q2 FY2025 ended June 30, 2025, up 100% y/y from $1.4M, with branded consumer products surging to $1.9M on Silly George momentum while contract manufacturing climbed 103% y/y to $0.9M; gross margins leaped to 43.6% from 20.3%, yet operating loss narrowed to $0.6M from $1.1M as SG&A rose 49% on marketing. YTD revenue hit $5.7M, up 110% y/y, with operating loss at $1.4M; diluted EPS of -$0.18 aligns with 7.65M shares, while net loss exceeded operating by $0.1M due to interest and other expenses. Cash dipped to $0.7M with $0.8M operating burn, offset by $0.6M notes payable and $0.3M financing leases at 9.1%; Silly George closed May 2024 for $0.6M (cash/stock mix), adding $0.6M indefinite-lived trademarks. Patent disputes with competitors pose removal risks for key eyelash products.
8-K
Q2 revenue doubles to $2.88M
NexGel reported Q2 2025 revenue of $2.88 million, doubling from $1.44 million a year earlier, while gross margins surged to 43.6% from 20.3%. Branded products and contract manufacturing drove the gains, narrowing net loss to $0.67 million. Revenue doubled year-over-year. The company holds to its $13 million full-year revenue target and positive EBITDA goal, bolstered by a $1 million STADA advance and $1.05 million in fresh financing.
8-K
NexGel appoints finance expert to board
NexGel appointed Steven A. Ciardiello, Shutterstock's Chief Accounting Officer, to its board of directors on July 31, 2025, adding him to the Audit Committee for a term until the 2026 annual meeting. With over 25 years in finance, including Big 4 accounting and roles at WeWork and AmTrust, Ciardiello brings expertise in SEC reporting and internal controls. The board granted him an option for 30,000 shares at $2.25, vesting monthly over 12 months. This bolsters governance amid growth, yet ties to unvested equity hinge on continued service.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
NEPH
Nephros, Inc.
4.85-0.01
NUWE
Nuwellis, Inc.
2.21+0.03
NXL
Nexalin Technology, Inc.
0.81-0.01
RGNT
Regentis Biomaterials Ltd.
6.05-0.84
SSKN
Strata Skin Sciences, Inc.
1.33-0.03
TELA
TELA Bio, Inc.
1.18+0.05
TFX
Teleflex Incorporated
124.87-1.85
UEEC
United Health Products, Inc.
0.06+0.00
ZYXI
Zynex, Inc.
0.34-0.32